The clinical efficacy and safety of four- weekly docetaxel as first-line therapy in elderly lung cancer patients with squamous cell carcinoma
- Authors
- Choi J.H.; Choi J.; Chung S.M.; Oh J.Y.; Lee Y.S.; Min K.H.; Hur G.Y.; Shim J.J.; Kang K.H.; Lee H.K.; Lee S.Y.
- Issue Date
- Jul-2019
- Publisher
- Korean National Tuberculosis Association
- Keywords
- Aged; Carcinoma; Carcinoma; Chemotherapy; Docetaxel; Lung Neoplasms; Non-Small-Cell Lung; Safety; Squamous Cell; Therapeutics; Treatment Outcome
- Citation
- Tuberculosis and Respiratory Diseases, v.82, no.3, pp 211 - 216
- Pages
- 6
- Indexed
- SCOPUS
ESCI
KCI
- Journal Title
- Tuberculosis and Respiratory Diseases
- Volume
- 82
- Number
- 3
- Start Page
- 211
- End Page
- 216
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/2681
- DOI
- 10.4046/trd.2018.0019
- ISSN
- 1738-3536
2005-6184
- Abstract
- Background: Docetaxel is one of the standard treatments for advanced non-small cell lung cancer. Docetaxel is usually administered in a 3-week schedule, but there is significant toxicity. In this phase II clinical study, we investigated the efficacy and safety of a 4-weekly schedule of docetaxel monotherapy, as first-line chemotherapy for advanced squamous cell carcinoma in elderly lung cancer patients. Methods: Patients with stage IIIB/ IV lung squamous-cell carcinoma age 70 or older, that had not undergone cytotoxic chemotherapy were enrolled. Patients received docetaxel 25 mg/m2 on days 1, 8, and 15, every 4 weeks. Primary endpoint was the objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity profiles. Results: A total of 19 patients were enrolled. Among 19 patients, 17 were for evaluated efficacy and safety. In the intentto- treat population, ORR and disease control rate (DCR) were 11.8% and 47.1%, respectively. In the response evaluable population, ORR was 16.7% and DCR was 66.7%. Median PFS and OS were 3.1 months and 3.3 months, respectively. There were three adverse grade 3/4 events. Grade 1 neutropenia was reported in one patient. Conclusion: Our data failed to demonstrate efficacy of a 4-weekly docetaxel regimen, in elderly patients with a poor performance status. However, incidence of side effects, including neutropenia, was lower than with a 3-week docetaxel regimen, as previously reported. © 2019 Korean National Tuberculosis Association. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Pulmonary, Allergy, and Critical Care Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.